Stryker Corporation 10-Q Summary: Period Ended June 30, 2004
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2004, and the six months ended on that date. Stryker Corporation is a global leader in orthopaedic and medical device markets, operating through two primary segments: Orthopaedic Implants and MedSurg Equipment. The report reflects a two-for-one stock split effective May 14, 2004, with all share and per-share data adjusted retroactively.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2004 | Six Months Ended June 30, 2004 |
|---|---|---|
| Net Sales | $1,043.0 million | $2,078.1 million |
| Gross Profit | $678.3 million (65.0% margin) | $1,345.2 million (64.7% margin) |
| Operating Income | $220.1 million (21.1% margin) | $413.3 million (19.9% margin) |
| Net Earnings | $152.7 million | $288.6 million |
| Diluted EPS | $0.37 | $0.70 |
| Cash from Operations | $44.7 million | $102.6 million |
| Cash and Equivalents | $62.6 million (as of June 30, 2004) | |
| Total Debt | $15.9 million outstanding |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% in Q2 and 20% for the first half of 2004 compared to the prior year. Growth was driven by increased unit volume, favorable product mix, and higher selling prices. Foreign currency fluctuations contributed approximately 3% to Q2 growth and 4% to the six-month growth.
- Profitability: Net earnings rose 42% in Q2 and 36% for the six-month period. Operating margins expanded due to improved manufacturing efficiencies and lower cost of sales percentages (35.0% in Q2 vs. 36.7% in 2003).
- Segment Performance: Orthopaedic Implants sales grew 15% in Q2, while MedSurg Equipment sales grew 21%. Physical Therapy Services revenue increased 11% in Q2.
- Debt Reduction: Interest expense dropped significantly (from $6.4 million to $1.8 million in Q2) as the company paid down borrowings and eliminated amounts outstanding under its accounts receivable securitization facility.
Guidance, Outlook, and Risks
- 2004 Outlook: Management expects diluted net earnings per share to approximate $1.13 for the full year, inclusive of an anticipated $0.29 per share charge related to the SpineCore acquisition. Net sales growth is projected in the range of 17% to 19%.
- SpineCore Acquisition: On July 21, 2004, Stryker announced a definitive agreement to acquire SpineCore, Inc. The deal involves a $120.0 million upfront cash payment and potential milestone payments up to $240.0 million. The upfront payment is expected to be written off as in-process R&D, resulting in an after-tax charge of approximately $120.0 million.
- Liquidity: The company maintains a $750.0 million revolving credit facility expiring in December 2006. With $797.2 million in available borrowing capacity and strong operating cash flow, management believes liquidity is sufficient for operations and future acquisitions.
- Risks: Key risks include regulatory actions affecting pricing, changes in third-party reimbursement levels, product liability claims, and foreign exchange volatility. Foreign currency translation adjustments reduced comprehensive earnings by $25.3 million in the first half of 2004.
Investor Verification Checklist
- Verify the timing and accounting treatment of the $120.0 million SpineCore acquisition charge in the upcoming Q3 2004 filing.
- Monitor the impact of foreign currency exchange rates on international sales, which accounted for 36% of total revenue in the first half of 2004.
- Review the aging of accounts receivable, as days sales outstanding increased to 60 days, attributed to aging domestic receivables and higher balances in Europe and Japan.
- Confirm the execution of the SpineCore merger and the subsequent inclusion of its results in consolidated operations.
- Assess the sustainability of gross margin expansion given the increase in R&D and SG&A expenses to support new product launches.